Nano Science and Technology InstituteNano Science and Technology Institute
Nano Science and Technology Institute 2005 NSTI Nanotechnology Conference & Trade Show
Nanotech 2005
Bio Nano 2005
Business & Investment
Nano Impact Workshop
Program
Sessions
Sunday
Monday
Tuesday
Wednesday
Thursday
Index of Authors
Index of Keywords
Keynote Presentations
Confirmed Speakers
Participating Companies
Industry Focus Sessions
Nanotech Expo
Special Symposia
Conferences
Sponsors
Exhibitors
Venue 2005
Organization
Press Room
Subscribe
Site Map
Nanotech 2005 At A Glance
Nanotech Proceedings
Nanotechnology Proceedings
Global Partner
nano tech
Supporting Organizations
Nanotech 2005 Supporting Organization
Media Sponsors
Nanotech 2005 Medias Sponsors
Event Contact
696 San Ramon Valley Blvd., Ste. 423
Danville, CA 94526
Ph: (925) 353-5004
Fx: (925) 886-8461
E-mail:
 
 

Colloidal Gold Nanoparticles: A Versatile Platform for Developing Tumor Targeted Cancer Therapies

G.F. Paciotti, L. Myer, D.G.I. Kingston, T. Ganesh and L. Tamarkin
CytImmune Sciences, Inc, US

Keywords:
colloidal gold nanoparticles, TNF, Paclitaxel, tumor targeted drug delivery

Abstract:
CytImmune Sciences is developing colloidal gold nanoparticles (cAu) as a platform for tumor targeted drug delivery. Specifically two drugs are discussed: Aurimune-T and AuriTax. Aurimune-T is manufactured by covalently linking molecules of TNF and Thiol-derivatized polyethylene glycol (PEG-THIOL) onto the surface of 25 nm colloidal gold. Intravenously administered Aurimune-T rapidly accumulates in solid tumors implanted in mice and shows little to no accumulation in the reticuloendothelial system or in other healthy organs. Coincident with the sequestration of gold is a 10-fold accumulation of TNF in the tumor when compared to animals treated with native TNF. By getting more TNF to the tumor Aurimune-T improves the safety and efficacy of TNF treatment since maximal tumor responses were achieved at lower doses of the drug. The second nanoparticle drug, AuriTax, consists of a tumor targeting moiety (TNF), a chemotherapeutic (paclitaxel), and PEG-THIOL, which are bound to the same cAu nanoparticle. Like Aurimune-T, AuriTax delivers 10-fold more TNF and paclitaxel to the solid tumor when compared to each drug alone. These data support the continued development of the colloidal gold platform and show the potential uses of TNF as a tumor targeting ligand and a cancer therapy.

Back to Program

Sessions Sunday Monday Tuesday Wednesday Thursday Authors

Nanotech 2005 Conference Program Abstract

 
Gold Sponsors
Nanotech Gold Sponsors
Silver Sponsors
Nanotech Silver Sponsors
Gold Key Sponsors
Nanotech Gold Key Sponsors
Nanotech Ventures Sponsors
Nanotech Ventures Sponsors
Sponsors
Nanotech Sponsors
News Headlines
NSTI Online Community
 
 

© Nano Science and Technology Institute, all rights reserved.
Terms of use | Privacy policy | Contact